235 related articles for article (PubMed ID: 15068500)
81. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis.
Riggs BL; O'Fallon WM; Lane A; Hodgson SF; Wahner HW; Muhs J; Chao E; Melton LJ
J Bone Miner Res; 1994 Feb; 9(2):265-75. PubMed ID: 8140940
[TBL] [Abstract][Full Text] [Related]
82. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
Cummings SR; Palermo L; Browner W; Marcus R; Wallace R; Pearson J; Blackwell T; Eckert S; Black D
JAMA; 2000 Mar; 283(10):1318-21. PubMed ID: 10714731
[TBL] [Abstract][Full Text] [Related]
83. Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Ben Sedrine W; Reginster JY
J Bone Miner Res; 2013 Apr; 28(4):807-15. PubMed ID: 23165656
[TBL] [Abstract][Full Text] [Related]
84. [Raloxifene (Celvista, Evista)].
Body JJ; Sternon J
Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
[TBL] [Abstract][Full Text] [Related]
85. Raloxifene for older women: a review of the literature.
Hansdóttir H
Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
[TBL] [Abstract][Full Text] [Related]
86. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
Barrett-Connor E; Ensrud KE; Harper K; Mason TM; Sashegyi A; Krueger KA; Anderson PW
Clin Ther; 2003 Mar; 25(3):919-30. PubMed ID: 12852708
[TBL] [Abstract][Full Text] [Related]
87. Raloxifene reduces vertebral fracture risk in postmenopausal women with osteoporosis.
Brandi ML
Clin Exp Rheumatol; 2000; 18(3):309-10. PubMed ID: 10895366
[No Abstract] [Full Text] [Related]
88. [Diagnostic imaging of treatment in osteoporosis: SERM].
Takada J; Iba K; Yamashita T
Clin Calcium; 2011 Jul; 21(7):1047-55. PubMed ID: 21719986
[TBL] [Abstract][Full Text] [Related]
89. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
[TBL] [Abstract][Full Text] [Related]
90. Selective estrogen-receptor modulators.
Cosman F
Clin Geriatr Med; 2003 May; 19(2):371-9. PubMed ID: 12916292
[TBL] [Abstract][Full Text] [Related]
91. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Grady D; Cauley JA; Geiger MJ; Kornitzer M; Mosca L; Collins P; Wenger NK; Song J; Mershon J; Barrett-Connor E;
J Natl Cancer Inst; 2008 Jun; 100(12):854-61. PubMed ID: 18544744
[TBL] [Abstract][Full Text] [Related]
92. Long-term effect of hormone therapy on bone in early menopause: vertebral fractures after 20 years.
Castelo-Branco C; Davila J; Perelló MF; Peguero A; Ros C; Martínez-Serrano MJ; Balasch J
Climacteric; 2014 Aug; 17(4):336-41. PubMed ID: 24313640
[TBL] [Abstract][Full Text] [Related]
93. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus.
Kanazawa I; Yamaguchi T; Yamamoto M; Yamauchi M; Yano S; Sugimoto T
Eur J Endocrinol; 2009 Feb; 160(2):265-73. PubMed ID: 18996964
[TBL] [Abstract][Full Text] [Related]
94. Performance of quantitative ultrasound measurements of bone for monitoring raloxifene therapy.
Paggiosi MA; Clowes JA; Finigan J; Naylor KE; Peel NF; Eastell R
J Clin Densitom; 2010; 13(4):441-50. PubMed ID: 20850365
[TBL] [Abstract][Full Text] [Related]
95. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.
Ha J; Kim J; Jeong C; Lim Y; Kim MK; Kwon HS; Song KH; Kang MI; Baek KH
Osteoporos Int; 2022 Jul; 33(7):1591-1599. PubMed ID: 35376989
[TBL] [Abstract][Full Text] [Related]
96. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
Cummings SR; Duong T; Kenyon E; Cauley JA; Whitehead M; Krueger KA;
JAMA; 2002 Jan; 287(2):216-20. PubMed ID: 11779264
[TBL] [Abstract][Full Text] [Related]
97. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.
Layton D; Clarke A; Wilton LV; Shakir SA
Osteoporos Int; 2005 May; 16(5):490-500. PubMed ID: 15309382
[TBL] [Abstract][Full Text] [Related]
98. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
Barrett-Connor E; Grady D; Sashegyi A; Anderson PW; Cox DA; Hoszowski K; Rautaharju P; Harper KD;
JAMA; 2002 Feb; 287(7):847-57. PubMed ID: 11851576
[TBL] [Abstract][Full Text] [Related]
99. Influence of Prevalent Vertebral Fracture on the Correlation between Change in Lumbar Spine Bone Mineral Density and Risk of New Vertebral Fracture: A Meta-Analysis of Randomized Clinical Trials.
Kobayashi T; Kaneko M; Narukawa M
Clin Drug Investig; 2020 Jan; 40(1):15-23. PubMed ID: 31630338
[TBL] [Abstract][Full Text] [Related]
100. Echogenic carotid artery plaques are associated with vertebral fractures in postmenopausal women with low bone mass.
Kim SH; Kim YM; Cho MA; Rhee Y; Hur KY; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
Calcif Tissue Int; 2008 Jun; 82(6):411-7. PubMed ID: 18496724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
